We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Evaluation of bone markers in hypophosphatemic rickets/osteomalacia.
- Authors
Nagata, Yuki; Imanishi, Yasuo; Ishii, Akira; Kurajoh, Masafumi; Motoyama, Koka; Morioka, Tomoaki; Naka, Hiroshi; Mori, Katsuhito; Miki, Takami; Emoto, Masanori; Inaba, Masaaki
- Abstract
N-terminal propeptide of type I procollagen (PINP) is a marker of newly formed type I collagen. However, its role in hypophosphatemic rickets/osteomalacia has not yet been established. Metabolic bone markers were examined in patients with oncogenic osteomalacia (OOM) and X-linked hypophosphatemic rickets (XLH), and in healthy controls. OOM and XLH patients were found to have hypophosphatemia secondary to elevated levels of serum fibroblast growth factor 23 (FGF-23). OOM patients had reduced levels of 1,25-dihydroxy vitamin D (1,25D) compared with XLH patients and healthy controls, despite attenuation of the reduction in these levels in the XLH patients secondary to active vitamin D supplementation. In contrast to patients with XLH, OOM patients showed a significant increase in serum PINP, which is suggestive of accelerated bone matrix formation. Bone alkaline phosphatase (BAP) and the BAP/PINP ratio were also increased in OOM but not in XLH patients, suggesting the presence of a disturbance in bone mineralization in OOM. Long-term supplementation of active form vitamin D and inorganic phosphate (IP) may have attenuated the defect in bone mineralization in the XLH patients, resulting in the normalization of PINP, BAP, and the BAP/PINP ratio. The present results suggest that, as with BAP, PINP is an appropriate metabolic bone marker in the assessment of hypophosphatemic rickets/osteomalacia.
- Subjects
COLLAGEN; OSTEOMALACIA; RICKETS; FIBROBLAST growth factors; ALKALINE phosphatase
- Publication
Endocrine (1355008X), 2011, Vol 40, Issue 2, p315
- ISSN
1355-008X
- Publication type
Letter
- DOI
10.1007/s12020-011-9512-z